Merck & Co., Inc. $MRK Shares Bought by Winnow Wealth LLC

Winnow Wealth LLC raised its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 2,147.6% in the third quarter, according to its most recent 13F filing with the SEC. The fund owned 12,654 shares of the company’s stock after buying an additional 12,091 shares during the period. Winnow Wealth LLC’s holdings in Merck & Co., Inc. were worth $1,063,000 at the end of the most recent quarter.

A number of other hedge funds have also recently modified their holdings of the stock. Chemung Canal Trust Co. lifted its stake in shares of Merck & Co., Inc. by 21.1% in the third quarter. Chemung Canal Trust Co. now owns 76,338 shares of the company’s stock worth $6,407,000 after buying an additional 13,285 shares in the last quarter. First Pacific Financial raised its holdings in Merck & Co., Inc. by 14.7% in the 3rd quarter. First Pacific Financial now owns 47,555 shares of the company’s stock valued at $3,991,000 after acquiring an additional 6,082 shares during the last quarter. Diversified Trust Co raised its holdings in Merck & Co., Inc. by 9.6% in the 3rd quarter. Diversified Trust Co now owns 207,838 shares of the company’s stock valued at $17,444,000 after acquiring an additional 18,187 shares during the last quarter. Caxton Associates LLP lifted its stake in Merck & Co., Inc. by 23.3% in the 2nd quarter. Caxton Associates LLP now owns 39,421 shares of the company’s stock worth $3,121,000 after purchasing an additional 7,458 shares in the last quarter. Finally, Live Oak Investment Partners lifted its stake in Merck & Co., Inc. by 209.1% in the 2nd quarter. Live Oak Investment Partners now owns 23,949 shares of the company’s stock worth $1,896,000 after purchasing an additional 16,202 shares in the last quarter. Hedge funds and other institutional investors own 76.07% of the company’s stock.

Merck & Co., Inc. Trading Up 1.8%

Shares of Merck & Co., Inc. stock opened at $110.24 on Friday. The stock has a 50 day moving average of $105.20 and a 200 day moving average of $91.87. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.44 and a current ratio of 1.66. The firm has a market capitalization of $273.62 billion, a price-to-earnings ratio of 14.56, a PEG ratio of 1.52 and a beta of 0.29. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $112.90.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, February 3rd. The company reported $1.94 EPS for the quarter, missing analysts’ consensus estimates of $2.08 by ($0.14). Merck & Co., Inc. had a net margin of 29.63% and a return on equity of 44.54%. As a group, research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Shareholders of record on Monday, March 16th will be given a $0.85 dividend. The ex-dividend date of this dividend is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a yield of 3.1%. Merck & Co., Inc.’s dividend payout ratio is presently 44.91%.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on MRK. The Goldman Sachs Group upped their price target on Merck & Co., Inc. from $92.00 to $120.00 and gave the company a “buy” rating in a research report on Tuesday, December 2nd. Wall Street Zen raised Merck & Co., Inc. from a “buy” rating to a “strong-buy” rating in a research note on Saturday. BMO Capital Markets raised Merck & Co., Inc. from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $82.00 to $130.00 in a research note on Thursday, December 18th. Weiss Ratings reiterated a “hold (c)” rating on shares of Merck & Co., Inc. in a report on Monday, December 29th. Finally, Wells Fargo & Company raised shares of Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $90.00 to $125.00 in a research report on Monday, November 24th. Eight analysts have rated the stock with a Buy rating, seven have given a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $114.53.

Merck & Co., Inc. News Roundup

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Zacks highlights strong Keytruda demand and new product launches as key upside drivers into Q4 results, supporting longer‑term revenue growth and helping sentiment today. Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
• Positive Sentiment: Insider/“smart money” activity: Chirfi Guindo bought roughly $1.06M of MRK stock — a buy by an institutional insider can signal confidence and attract momentum buyers. Smart Money Move: Chirfi Guindo Grabs $1.06M Worth Of Merck & Co Stock
• Positive Sentiment: Zacks’ market recap notes MRK outperformed while the broader market dipped, indicating relative strength and sector‑specific buying interest. Why the Market Dipped But Merck (MRK) Gained Today
• Neutral Sentiment: Analyst notes and sector coverage (Globe and Mail) provide mixed, mostly informational views on Merck alongside peers—useful for context but not a clear directional trigger. Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and Waters (WAT)
• Neutral Sentiment: Additional analyst commentary comparing MRK with UnitedHealth provides sector perspective but no new catalyst. Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and UnitedHealth (UNH)
• Neutral Sentiment: Zacks’ primer on Wall Street estimates and key metrics ahead of Q4 is a useful reference for modeling MRK’s upcoming quarter but doesn’t itself move the needle. Curious about Merck (MRK) Q4 Performance? Explore Wall Street Estimates for Key Metrics
• Neutral Sentiment: Zacks notes MRK is a trending stock on its platform—higher retail/institutional attention increases liquidity and volatility risk but is not a directional catalyst by itself. Merck & Co., Inc. (MRK) Is a Trending Stock: Facts to Know Before Betting on It
• Negative Sentiment: Zacks warns that declining analyst estimates and rising M&A‑related costs could depress near‑term results and investor sentiment—key risk ahead of earnings. Buy, Sell or Hold MRK Stock: Key Factors to Watch Before Q4 Earnings
• Negative Sentiment: Brokerage consensus is an average “Hold” rating, indicating limited near‑term upgrade potential and less bullish analyst conviction. Merck & Co., Inc. (NYSE:MRK) Given Average Rating of “Hold” by Brokerages

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP David Michael Williams sold 8,614 shares of Merck & Co., Inc. stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $83.59, for a total transaction of $720,044.26. Following the completion of the sale, the executive vice president directly owned 24,578 shares in the company, valued at $2,054,475.02. This trade represents a 25.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.13% of the stock is currently owned by company insiders.

Merck & Co., Inc. Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.